
In the Claims

- 1. (Original) A composition for coating an implantable device comprising
- (1) a first block copolymer comprising a block having a glass transition temperature (T_g) below about body temperature and a second block having a T_g or a melting temperature (T_m) above about body temperature, and
- (2) a material selected from the group consisting of a biobeneficial polymer capable of forming a conjugate with the first block copolymer, a second block copolymer and combination thereof, wherein the second block copolymer comprising
 - (i) a biobeneficial component; and
 - (ii) a component selected from the group consisting of components miscible with the first block copolymer and components insoluble in water,
- 2. (Original) The composition of claim 1 wherein the block having a T_g above about body temperature has a structure of Formula I and the block having a T_g below about body temperature has a structure of Formula II:



wherein R_1 , R_2 , R_3 and R_4 are independently hydrogen, phenyl, methyl, ethyl, acrylate, or methacrylate, with the proviso that R_1 , R_2 , R_3 and R_4 can not all be hydrogen;

wherein R_5 and R_7 are independently methyl, ethyl, propyl, butyl, benzyl, or phenyl; and wherein R_6 and R_8 are independently hydrogen, methyl, ethyl, propyl, benzyl, or phenyl.

3. (Original) The composition of claim 1 wherein the first block copolymer has the following structure:

$$\begin{array}{c|c} & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & \\ & & \\ &$$

Formula III

- 4: (Original) The composition of claim 1 wherein the biobeneficial polymer is covalently attached to the first block copolymer via a chemical linkage.
- 5. (Original) The composition of claim 3 wherein the biobeneficial polymer is covalently attached to the phenyl ring of the structure of Formula III.
- 6. (Original) The composition of claim 5 wherein the biobeneficial polymer is selected from the group consisting of poly(ethylene glycol), poly(propylene glycol), PLURONIC™ surfactants, poly(tetramethylene glycol), hydroxy functional poly(vinyl pyrrolidone), dextran, dextrin, sodium hyaluronate, hyaluronic acid, heparin, Elastin, Chitosan, poly(2-hydroxyethyl methacrylate), sulphonated poly(styrene), poly(3-hydroxypropyl methacrylamide), 4-amino-2,2',6,6'-tetrapiperidine oxide, stable nitroxides, super oxide dimutase mimics, free radical scavengers and combinations thereof.
- 7. (Original) The composition of claim 6 wherein the conjugate has the structure of Formula IV:

$$\begin{array}{c|c} & & & & \\ & &$$

8. (Original) The composition of claim 6 wherein the conjugate has the structure of Formula V:

- 9. (Original) The composition of claim 1 wherein the component of the second block copolymer miscible with the first block copolymer is a hydrophobic material.
- 10. (Original) The composition of claim 1 wherein the second block copolymer is selected from the group consisting of polystyrene-polyisobutylene-polystyrene block copolymer

(SIS), polystyrene, polyisobutylene, polycaprolactone (PCL), poly(L-lactide), poly(D,L-lactide), poly(lactides), poly(lactide-co-glycolide), poly(glycolide), polylactic acid (PLA), polyalkylene, polyfluoroalkylene, polyhydroxyalkanoate, poly(3-hydroxybutyrate), poly(4-hydroxybutyrate), poly(3-hydroxyvalerate), poly(3-hydroxybutyrate-co-3-hydroxyvalerate), poly(3-hydroxybutyrate), poly(4-hdyroxybexanoate), mid chain polyhydroxyalkanoate, poly (trimethylene carbonate), poly (ortho ester), polyphosphazenes, poly(phosphoester), poly(tyrosine derived arylates), poly(tyrosine derived carbonates), and a combination thereof.

- 11. (Original) The composition of claim 1 wherein the water insoluble component is selected from the group consisting of polydimethyloxanone (PDMS), polyvinylidene fluoride (PVDF), polyhexafluoropropylene (HFP), polydimethylsiloxane, poly (vinylidene fluoride-co-hexafluoropropylene) (PVDF-HFP), poly(vinylidene fluoride-co-chlorotrifluoroethylene) (PVDF-CTFE), poly(butyl methacrylate), poly(methyl methacrylate), poly(methyl methacrylate), poly(methyl methacrylate), poly(vinyl acetate), poly(ethylene-co-vinyl acetate), poly(ethylene-co-vinyl alcohol), poly(ester urethanes), poly(ether-urethanes), poly(carbonate-urethanes), poly(silicone-urethanes), and poly(urea-urethanes), and a combination thereof.
- 12. (Original) The composition of claim 1 wherein the biobeneficial component of the second block copolymer is selected from the group consisting of poly(ethylene glycol), poly(propylene glycol), PLURONIC™ surfactants, poly(tetramethylene glycol), hydroxy functional poly(vinyl pyrrolidone), dextran, dextrin, sodium hyaluronate, hyaluronic acid, heparin, Elastin, Chitosan, poly(2-hydroxyethyl methacrylate), sulphonated poly(styrene), poly(3-hydroxypropyl methacrylamide), 4-amino-2,2',6,6'-tetrapiperidine oxide, stable nitroxides, super oxide dimutase mimics, free radical scavengers and combinations thereof.
- 13. (Original) The composition of claim 1 wherein the second block copolymer is selected from the group consisting of SIS-PEG, polystyrene-PEG, polyisobutylene-PEG, PCL-

PEG, PLA-PEG, PDMS-PEG, PVDF-PEG, SIS-hyaluronic acid (HA), polystyrene-HA, polyisobutylene-HA, PCL-HA, PLA-HA, PMMA-HA, PVDF-HA, SIS-heparin, polystyrene-heparin, polyisobutylene-heparin, PCL-heparin, PLA-heparin, PMMA-heparin, and PVDF-heparin.

- 14. (Original) The composition of any of claims 1-13 further comprising a bioactive agent.
- 15. (Original) The composition of claim 14 wherein the bioactive agent is selected from the group consisting of proteins, peptides, anti-inflammatory agents, antivirals, anticancer drugs, anticoagulant agents, free radical scavengers, Everolimus, sirolimus, sirolimus derivatives, paclitaxel, estradiol, steroidal anti-inflammatory agents, antibiotics, nitric oxide donors, super oxide dismutases, super oxide dismutases mimics, 4-amino-2,2,6,6-tetramethylpiperidine-1-oxyl (4-amino-TEMPO), tacrolimus, dexamethasone, rapamycin, 40-*O*-(3-hydroxy)propyl-rapamycin, 40-*O*-[2-(2-hydroxy)ethoxy]ethyl-rapamycin, and 40-*O*-tetrazole-rapamycin, ABT-578, clobetasol, cytostatic agents, and a combination thereof.
- 16. (Original) The composition of claim 15 wherein the free radical scavenger is super oxide dismutase.
- 17. (Original) The composition of claim 15 wherein the bioactive agent is a therapeutic drug for the treatment of restenosis.
- 18. (Original) An implantable device comprising a coating which comprises a composition as defined in accordance with any of claims 1-13.
 - 19. (Original) The implantable device of claim 18 further comprises a bioactive agent.
- 20. (Original) The implantable device of claim 18 wherein the bioactive agent is selected from the group consisting of proteins, peptides, anti-inflammatory agents, antivirals, anticancer drugs, anticoagulant agents, free radical scavengers, Everolimus, sirolimus

derivatives, paclitaxel, estradiol, steroidal anti-inflammatory agents, antibiotics, nitric oxide donors, super oxide dismutases, super oxide dismutases mimics, 4-amino-2,2,6,6-tetramethylpiperidine-1-oxyl (4-amino-TEMPO), tacrolimus, dexamethasone, rapamycin, 40-*O*-(3-hydroxy)propyl-rapamycin, 40-*O*-[2-(2-hydroxy)ethoxy]ethyl-rapamycin, and 40-*O*-tetrazole-rapamycin, ABT-578, clobetasol, cytostatic agents, and a combination thereof.

- 21. (Original) The implantable device of claim 19 wherein the free radical scavenger is super oxide dismutase.
- · 22. (Original) The implantable device of claim 19 wherein the bioactive agent is a therapeutic drug.
 - 23. (Original) The implantable device of claim 18 which is a stent.
 - 24. (Original) The implantable device of claim 19 which is a DES.
 - 25. (Original) The implantable device of claim 20 which is a DES.
 - 26. (Original) The implantable device of claim 21 which is a DES.
 - 27. (Original) The implantable device of claim 22 which is a DES.
- 28. (Original) A method of coating an implantable device comprising coating a composition as defined in claim 1.
- 29. (Original) The method of claim 28 wherein the composition further comprising a bioactive agent.
- 30. (Original) A method of treating a disorder in an animal by implanting in the animal the implantable device of claim 18.
 - 31. (Original) The method of claim 30 wherein the implantable device is a stent.
- 32. (Original) The method of claim 30 wherein the composition further comprises a bioactive agent.

- 33. (Original) The method of claim 32 wherein the bioactive agent is selected from the group consisting of proteins, peptides, anti-inflammatory agents, antivirals, anticancer drugs, anticoagulant agents, free radical scavengers, Everolimus, sirolimus, sirolimus derivatives, paclitaxel, estradiol, steroidal anti-inflammatory agents, antibiotics, nitric oxide donors, super oxide dismutases, super oxide dismutases mimics, 4-amino-2,2,6,6-tetramethylpiperidine-1-oxyl (4-amino-TEMPO), tacrolimus, dexamethasone, rapamycin, 40-*O*-(3-hydroxy)propyl-rapamycin, 40-*O*-[2-(2-hydroxy)ethoxy]ethyl-rapamycin, and 40-*O*-tetrazole-rapamycin, ABT-578, clobetasol, cytostatic agents, and a combination thereof.
- 34. (Original) The method of claim 33 wherein the free radical scavenger is super oxide dismutase.
- 35. (Original) The method of claim 32 wherein the bioactive agent is a therapeutic drug.
- 36. (Currently amended) The method of claim 28 wherein the implantable device which is a stent.
 - 37. (Original) The method of claim 32 which is a DES.
 - 38. (Original) The method of claim 33 which is a DES.
 - 39. (Original) The method of claim 34 which is a DES.
 - 40. (Original) The method of claim 35 which is a DES.
 - 41. (Canceled)
 - 42. (Canceled)
- 43. (Original) The method of claim 30 wherein the animal is a human, and wherein disorder is selected from the group consisting of stenosis, occlusions of the arterial vasculature, and vulnerable plaque
 - 44. (Original) The method of claim 31 wherein the animal is a human, and

wherein disorder is selected from the group consisting of stenosis, occlusions of the arterial vasculature, and vulnerable plaque.

- 45. (Original) The method of claim 32 wherein the animal is a human, and wherein disorder is selected from the group consisting of stenosis, occlusions of the arterial vasculature, and vulnerable plaque.
- 46. (Original) The method of claim 33 wherein the animal is a human, and wherein disorder is selected from the group consisting of stenosis, occlusions of the arterial vasculature, and vulnerable plaque.
- 47. (Original) The method of claim 34 wherein the animal is a human, and wherein disorder is selected from the group consisting of stenosis, occlusions of the arterial vasculature, and vulnerable plaque.
 - 48. (Canceled)
- 49. (Original) The method of claim 37 wherein the animal is a human, and wherein disorder is selected from the group consisting of stenosis, occlusions of the arterial vasculature, and vulnerable plaque.
- 50. (Original) The method of claim 38 wherein the animal is a human, and wherein disorder is selected from the group consisting of stenosis, occlusions of the arterial vasculature, and vulnerable plaque.
- 51. (Original) The method of claim 39 wherein the animal is a human, and wherein disorder is selected from the group consisting of stenosis, occlusions of the arterial vasculature, and vulnerable plaque.
- 52. (Original) The method of claim 40 wherein the animal is a human, and wherein disorder is selected from the group consisting of stenosis, occlusions of the arterial vasculature, and vulnerable plaque.

53. (Canceled)